Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose safety, tolerability, PK and PD study of HT-101 injection and/or HT-102 injection in chronic HBV infection
CTR20244730Phase 2Active
- Sponsor
- Xingyao Kunze
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HT-101, HT-102 in Chronic Hepatitis B (CHB), sponsored by Xingyao Kunze. Started Dec 2024; status: active.
02
Drugs
HT-101HT-102
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20244730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244730.